SRT1720 HCl

Catalog No.S1129

For research use only.

SRT1720 HCl is a selective SIRT1 activator with EC50 of 0.16 μM in a cell-free assay, but is >230-fold less potent for SIRT2 and SIRT3. SRT1720 induces autophagy.

SRT1720 HCl Chemical Structure

CAS No. 1001645-58-4

Selleck's SRT1720 HCl has been cited by 154 publications

Purity & Quality Control

Choose Selective Sirtuin Inhibitors

Other Sirtuin Products

Biological Activity

Description SRT1720 HCl is a selective SIRT1 activator with EC50 of 0.16 μM in a cell-free assay, but is >230-fold less potent for SIRT2 and SIRT3. SRT1720 induces autophagy.
Targets
SIRT1 [1]
(Cell-free assay)
0.16 μM(EC50)
In vitro

The maximum activation ratio of SRT1720 versus the closest sirtuin homologues, SIRT2 (EC1.5 = 37 μM) and SIRT3 (EC1.5 > 300 μM) is up to 781%. SRT1720 binds to the SIRT1 enzyme-peptide substrate complex at an allosteric site amino-terminal to the catalytic domain and lower the Michaelis constant for acetylated substrates. SRT1720 could reduce fed glucose levels. Glucose excursion during an intraperitoneal glucose tolerance test is also significantly reduced in the SRT1720 group, and comparable to rosiglitazone, a PPARγ activator that has been used to treat type 2 diabetes. SRT1720 does not have an effect on fasting glucose in chow-fed mice, revealing that pharmacological SIRT1 activation is unlikely to induce hypoglycaemia. SRT1720 significantly reduces the hyperinsulinaemia after 4 weeks, partially normalizing increased insulin levels similar to rosiglitazone treatment. SRT1720 treatment increases mitochondrial capacity by 15% in gastrocnemius muscle as measured by citrate synthase activity. [1] Higher concentrations of SRT1720 (15 μM) induces a modest (10-20%) decrease in normal cell viability. SRT1720 also significantly inhibits VEGF-dependent MM cell migration. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CACs  MXjGeY5kfGmxbjDBd5NigQ>? MnXzOOKh|ryP Ml\ON|DDqG2rbh?= MX3EUXNQ NHLM[YlqdmS3Y3XzJIFkfXSnIGPJVnQyKGGldHn2ZZRqd28EoB?= M2jjZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkW0NVA1Lz5{NkK1OFExPDxxYU6=
MC3T3-E1 MUPGeY5kfGmxbjDBd5NigQ>? M4rIWVExKML3TdMg MXOxJIg> NUXKeGxHemWmdXPld{B1cGViVFfGMe6zNXO2aX31cIF1\WRiVlXHSkBz\WynYYPlJIlvKGSxc3WtJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYNCpC=> M4HpRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO2PVc5Lz5{NkGzOlk4QDxxYU6=
MC3T3-E1 NEnqN2tHfW6ldHnvckBCe3OjeR?= M3L0fVExKML3TdMg M{fhTVEzKGh? MXTy[YR2[2W|IITo[UBXTUeIIH3SUmEh\XiycnXzd4lwdiCuZY\lcJMhe3SrbYXsZZRm\CCkeTDUS2Yu|rJ? MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|Nkm3PEc,OjZzM{[5O|g9N2F-
MC3T3-E1 MoXxSpVv[3Srb36gRZN{[Xl? M4fVfVIxKM7:TR?= NUfFPHFiOSCq MVXzeZBxemW|c3XzJJRp\SCWR1[t{tIucW6mdXPl[EBxcG:|cHjvdplt[XSrb36gc4YheDR2L4C0NkBOSVBia3nuZZNmKG:{IGPBVGswUk6N M4DiNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO2PVc5Lz5{NkGzOlk4QDxxYU6=
WE-68 MUjBdI9xfG:|aYOgRZN{[Xl? MojtNE0zPCEQvF2= NUXncnRzOjRiaB?= Mln6bY5lfWOnczDj[YxtKGSnYYToJIlvKGSxc3Wg[IVx\W6mZX70cJk> NInRS5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC1OVgxPSd-Mk[wOVU5ODV:L3G+
SK-ES-1 NH3rb3BCeG:ydH;zbZMhSXO|YYm= NX60ZWlbOC1zMDFOwG0> MXGyOEBp MnrQbY5lfWOnczDj[YxtKGSnYYToJIlvKGSxc3Wg[IVx\W6mZX70cJk> M3LxeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEW1PFA2Lz5{NkC1OVgxPTxxYU6=
SK-N-MC  M1TDNWFxd3C2b4Ppd{BCe3OjeR?= NHK2ZpAxNTJwNTFOwG0> M3jQTVI1KGh? Mm\SbY5lfWOnczDj[YxtKGSnYYToJIlvKGSxc3Wg[IVx\W6mZX70cJk> MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB3NUiwOUc,OjZyNUW4NFU9N2F-
WE-68 M{niXGZ2dmO2aX;uJGF{e2G7 NUewRm5vOjBizszN MYOwMVI1KGh? M1TseoFkfGm4YYTld{Bk[XOyYYPlJFMwPw>? M3y3VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEW1PFA2Lz5{NkC1OVgxPTxxYU6=
SK-ES-1 MkGxSpVv[3Srb36gRZN{[Xl? M2ixcVExKM7:TR?= MUiwMVI1KGh? M4HGfoFkfGm4YYTld{Bk[XOyYYPlJFMwPw>? MoW0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNUW4NFUoRjJ4MEW1PFA2RC:jPh?=
SK-N-MC  MV7GeY5kfGmxbjDBd5NigQ>? M{HYc|Mh|ryP MmS1NE0zPCCq NIqzVpJi[3SrdnH0[ZMh[2G|cHHz[UA{Nzd? MlT1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNUW4NFUoRjJ4MEW1PFA2RC:jPh?=
NRK-49F NFTEO4ZHfW6ldHnvckBCe3OjeR?= MViw5qCUOsLizszN M{XvUVM3KGh? MYnpcoNz\WG|ZYOg[ZhxemW|c3nvckBw\iEQsT3TUWEh[W6mIH\pZpJwdmWldHnuJIRwe2ViZHXw[Y5l\W62bIm= MoDHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkKwNFMoRjJ4MEKyNFA{RC:jPh?=
NRK-49F NYj4VlFwTnWwY4Tpc44hSXO|YYm= Ml3ZNQKBmzMEoN88US=> NHPPfWI{PiCq NF3RO5lmdmijbnPld{BxcG:|cHjvdplt[XSrb36gc4YhTUeIUjDhcoQhWESJRmNOtuKh MmrGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkKwNFMoRjJ4MEKyNFA{RC:jPh?=
NRK-49F Ml:zSpVv[3Srb36gRZN{[Xl? NIrrSVQx6oDVMtMg{txO NHTDU4Q{PiCq NVG1UZdO\W6qYX7j[ZMhW1SDVEOgdIhwe3Cqb4L5cIF1cW:w NYW2VFVSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlIxODNpPkK2NFIzODB|PD;hQi=>
RAW264.7 M3z1eGZ2dmO2aX;uJGF{e2G7 M2[zeFEh|ryP NY[3Z2lKPiCq M1jQTZVxemWpdXzheIV{KHSqZTDy[YR2[2WmIGPJVnQyKHC{b4TlbY4hd3JibWLORUBt\X[nbIOgZpkhcGmpaDDncJVkd3On MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd7M{m5OUc,OjV5OUO5PVU9N2F-
MCF10A M2m4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVqwMVIxKM7:TR?= NV3FOINSOjRiaB?= NET5bXRz\WS3Y3XzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? M2DiRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEGxN|U3Lz5{NUSxNVM2PjxxYU6=
MCF-7 Mn3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{T3PFAuOjBizszN Mnz0NlQhcA>? M2H6cJJm\HWlZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MnnOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MUGzOVYoRjJ3NEGxN|U3RC:jPh?=
T47D M3LxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYWwMVIxKM7:TR?= NVnyfHExOjRiaB?= MkHUdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MoHTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MUGzOVYoRjJ3NEGxN|U3RC:jPh?=
SKBR3 NGCzfnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TnNlAuOjBizszN NH\6b2UzPCCq Ml24doVlfWOnczDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NXjkPGtZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVE{PTZpPkK1OFEyOzV4PD;hQi=>
MDA-MB-231 NVTENosyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWD6NoI3OC1{MDFOwG0> NFL2eVAzPCCq MXLy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzMUO1Okc,OjV2MUGzOVY9N2F-
SUM149 NIf2bW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3iyTFAuOjBizszN M{LZdFI1KGh? M2PwNZJm\HWlZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzMUO1Okc,OjV2MUGzOVY9N2F-
HS578T NU\CTHg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3K0cVAuOjBizszN MYWyOEBp M2LlUpJm\HWlZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NWrsV|kyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVE{PTZpPkK1OFEyOzV4PD;hQi=>
BT20 MmjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYftbGl4OC1{MDFOwG0> NIWzVGkzPCCq NXzwbVlIemWmdXPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NXW0cGR2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVE{PTZpPkK1OFEyOzV4PD;hQi=>
A459 NX;Fd2lnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\SNE0zOCEQvF2= MVeyOEBp MmrMdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 M{XVN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEGxN|U3Lz5{NUSxNVM2PjxxYU6=
HCT116 M2G1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXlSoY{OC1{MDFOwG0> NYq1XoRTOjRiaB?= MX3y[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> NV;K[phnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVE{PTZpPkK1OFEyOzV4PD;hQi=>
Neu NHnKV|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHOxfGMxNTJyIN88US=> MXqyOEBp NFy0Uppz\WS3Y3XzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? M2fQW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEGxN|U3Lz5{NUSxNVM2PjxxYU6=
MDA-MB-231 NIW3e2RHfW6ldHnvckBCe3OjeR?= MnzlOUDPxE1? M3Xn[VghcA>? MXPpcoNz\WG|ZYOgeIhmKG63bXLldkBw\iCjY3nkbYMhfmW|aXP1cIFzKG:{Z3Hu[Yxt\XN? M{PaVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEGxN|U3Lz5{NUSxNVM2PjxxYU6=
MDA-MB-231 M2nzfmZ2dmO2aX;uJGF{e2G7 NUPNdJg5PSEQvF2= NFfRPI8yPiCq NV\YdXZqcW6mdXPld{BtgXOxc3;tZYwhdWWvYoLhcoUheGW{bXXhZoltcXqjdHnvci=> MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzMUO1Okc,OjV2MUGzOVY9N2F-
MC3T3-E1 MY\GeY5kfGmxbjDBd5NigQ>? NUHXbVNoOTBizszN M2PZeFYxKG2rbtMg MkPWd5VxeHKnc4Pld{B1cGViRlfGMVIue3SrbYXsZZRm\CCxc4Tlc5Bzd3SnZ3XybY4hemWuZXHz[S=> NXv6XoliRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyPVAxQTVpPkK1NlkxODl3PD;hQi=>
MC3T3-E1 NWH0e2pXTnWwY4Tpc44hSXO|YYm= MWexNEDPxE1? M{PrXlYxKG2rbtMg NF\NfmtifHSnboXheIV{KHSqZTDGS2YuOi2rbnT1Z4VlKG:|dHXvdJJwfGWpZYLpckBuWk6DIHX4dJJme3Orb36= NYC4ZZp7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyPVAxQTVpPkK1NlkxODl3PD;hQi=>
MC3T3-E1 NXvZWphHTnWwY4Tpc44hSXO|YYm= MVexNEDPxE1? MkPwOlAhdWmwwrC= M4T4UYF1fGWwdXH0[ZMhfGinIF\HSk0zNWmwZIXj[YQhd3O2ZX;wdo91\WencnnuJI1TVkFiZYjwdoV{e2mxbh?= NEjmeG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK5NFA6PSd-MkWyPVAxQTV:L3G+
MC3T3-E1 NIi3T|ZHfW6ldHnvckBCe3OjeR?= NHvpNVMyOCEQvF2= MkXZOlAhdWmwwrC= NG\HN2N{fXCycnXzd4V{KHSqZTDCUXAuPC2|dHnteYxifGWmIG\FS2YhemWuZXHz[S=> MmDzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2M{W0OFQoRjJ2NEO1OFQ1RC:jPh?=
MC3T3-E1 MlzUSpVv[3Srb36gRZN{[Xl? MX[xNEDPxE1? NIPY[5Q3OCCvaX9CpC=> NE\MfIV{fXCycnXzd4V{KHSqZTDQS2Yz|rFvc4TpcZVt[XSnZDDPVGchemWuZXHz[S=> NHXYPWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOzN|M{Pid-MkSzN|M{OzZ:L3G+
MC3T3-E1 NFSzcFdHfW6ldHnvckBCe3OjeR?= NXzQOWtpOTBizszN NVHncFdJPjBibXnuxsA> MUjy[YR2[2W|IITo[UBRT0Z{zsGtd5RqdXWuYYTl[EBxcG:|cHjvdplt[XSrb36gc4YheDR2L4C0NkBOSVBia3nuZZNm Ml3oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|M{OzN|YoRjJ2M{OzN|M3RC:jPh?=
MC3T3-E1 MlHBSpVv[3Srb36gRZN{[Xl? M4jqNVExKM7:TR?= M1zLZVYxKG2rbtMg NFSwZ3BifHSnboXheIV{KHSqZTDQS2Yz|rFvaX7keYNm\CCyaH;zdIhwenmuYYTpc44hd2ZiYn;0bEBOTUtzL{KgZY5lKFKjZj2x MoXsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|M{OzN|YoRjJ2M{OzN|M3RC:jPh?=
RPE NXrSVFZ1S2WubDDWbYFjcWyrdImgRZN{[Xl? MYK1JOK2VQ>? M1rRSVEhcA>? NECycndifHSnboXheIV{KE:DzsKtbY5lfWOnZDDk[YNz\WG|ZTDv[kBk\WyuII\pZYJqdGm2eR?= NFvrSHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECzOlk{QCd-MkSwN|Y6Ozh:L3G+
9607 NXf4[mF[S2WubDDWbYFjcWyrdImgRZN{[Xl? MWmxJO69VQ>? NGqzUG0{PiCq NU\KWIJ3cW6lcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClb33wZZJm\CC5aYToJI1mdGG2b37pckBidG:wZR?= Mmq4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mk[5OFkoRjJ|N{K2PVQ6RC:jPh?=
9607 Mk[4SpVv[3Srb36gRZN{[Xl? MnqzNUDPxE1? NHO1PYo{PiCq MlqzbY5kemWjc3XzJHNKWlRzIHHu[EBl\WO{ZXHz[YQh[WOndInsZZRm\C2yNUOg[ZhxemW|c3nvci=> NWnjdndxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3NlY6PDlpPkKzO|I3QTR7PD;hQi=>
RPMI.8226 M1rkOWNmdGxiVnnhZoltcXS7IFHzd4F6 MXW3M|ExKM7:TR?= MYmyOEBp M3fleYRm[3KnYYPld{B3cWGkaXzpeJkh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=> NFfnb3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm1NFczQCd-MkG5OVA4Ojh:L3G+
U266 NXPvXYpyS2WubDDWbYFjcWyrdImgRZN{[Xl? NWrzTlVSPy9zMDFOwG0> NH30fHMzPCCq MlnK[IVkemWjc3XzJJZq[WKrbHn0fUBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 NVX3VZdJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OVA4OjhpPkKxPVUxPzJ6PD;hQi=>
MM.1S MULD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NEHubmQ4NzFyIN88US=> MYGyOEBp MY\k[YNz\WG|ZYOgeoli[mmuaYT5JINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl3MEeyPEc,OjF7NUC3Nlg9N2F-
KMS12 NELLcpFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NEHNZXE4NzFyIN88US=> M2PRRlI1KGh? Mn;M[IVkemWjc3XzJJZq[WKrbHn0fUBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 NGXHTGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm1NFczQCd-MkG5OVA4Ojh:L3G+
LR5 NHL4[YpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1vWXVcwOTBizszN NUP5UVRCOjRiaB?= Mn7P[IVkemWjc3XzJJZq[WKrbHn0fUBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl3MEeyPEc,OjF7NUC3Nlg9N2F-
MM.1R NFXXTZpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGfD[YU4NzFyIN88US=> NHLMT|MzPCCq NVexUpRi\GWlcnXhd4V{KH[rYXLpcIl1gSClb37j[Y51emG2aX;uJIRmeGWwZHXueIx6 M{jzPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUWwO|I5Lz5{MUm1NFczQDxxYU6=
Ina6 NWO5Z21TS2WubDDWbYFjcWyrdImgRZN{[Xl? NILqfYE4NzFyIN88US=> NXLXbJpLOjRiaB?= M1;sN4Rm[3KnYYPld{B3cWGkaXzpeJkh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=> M2LiTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUWwO|I5Lz5{MUm1NFczQDxxYU6=
RPMI-8226 MVzBdI9xfG:|aYOgRZN{[Xl? NVTlPHJEPy9zMDFOwG0> MnLBNlQhcA>? Moq5bY5lfWOnczDhJJNq\26rZnnjZY51KGmwY4LlZZNmKGmwIITo[UBCdm6neHnuJHYsN1CL4pkSxsBieG:ydH;zbZM> M2KzflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUWwO|I5Lz5{MUm1NFczQDxxYU6=
MM.1R  MmntRZBweHSxc3nzJGF{e2G7 NEW3Zlc4NzFyIN88US=> MWSyOEBp NXvrOIpvcW6mdXPld{BiKHOrZ37p[olk[W62IHnuZ5Jm[XOnIHnuJJRp\SCDbn7lfIlvKFZtL2DJ5qiTyqCjcH;weI9{cXN? MkPTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NUC3NlgoRjJzOUWwO|I5RC:jPh?=
H411EC3 M13nS2Z2dmO2aX;uJGF{e2G7 M3S4d|UxNzFyMDDuUS=> MVu2JIg> NULQcJpTcW6lcnXhd4V{KFOLUmSxJIFkfGm4aYT5JIlvKHSqZTDwdoV{\W6lZTDv[kBVW0FuIGDFVGNMKGGldHn2bZR6NCCvUl7BJIxmfmWuczDv[kBR[2tzIHHu[EBR\2NzzsGsJIFv\CCnbHX2ZZRqdmdiZ3z1Z49{\SCycn;keYN1cW:w NFjYeFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUKxNlA6Pid-MkGyNVIxQTZ:L3G+
hepatocytes NGPUeZNHfW6ldHnvckBCe3OjeR?= NFXXV|EyOCCwTR?= MX[2JIg> NIS0WJRqdmO{ZXHz[ZMhW0mUVEGgZYN1cX[rdImgbY4hfGinIIDy[ZNmdmOnIH;mJHRUSSxiUFXQR2sh[WO2aY\peJktKG2UTlGgcIV3\Wy|IH;mJHBkczFiYX7kJHBo[zIQsTygZY5lKGWuZY\heIlv\yCpbIXjc5NmKHC{b3T1Z5Rqd25? NH\EWIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUKxNlA6Pid-MkGyNVIxQTZ:L3G+
hepatocytes MlzSSpVv[3Srb36gRZN{[Xl? NGW0XZMyOCCwTR?= MXS2JIg> M{HZdYlv[3KnYYPld{BJdWelctMgZY5lyqCDY3RCpIdmdmViZYjwdoV{e2mxbh?= M{LSfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkGyNFk3Lz5{MUKxNlA6PjxxYU6=
U2OS NF[5XndHfW6ldHnvckBie3OjeR?= MU[wMlExKHWP NILydIFC[3SrdnH0bY9vKG:oIGPJVnQyKGmwIHj1cYFvKFV{T2OgZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4heDV|IHTlZYNmfHmuYYTpc44hdGW4ZXygZZQhOC5zMDD1US=> MmTvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyNE[0NFkoRjF6MES2OFA6RC:jPh?=
A673 NVrTeI5ueUiWUzDhd5NigQ>? NF6zeGdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?= MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
DAOY MXjxTHRUKGG|c3H5 NVvlZXJ3eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFTBU3kh[2WubIO= Mom0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-37 M4LxdZFJXFNiYYPzZZk> NWjrfpEzeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz M1i1b|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD MWfxTHRUKGG|c3H5 NFiyZXlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUlSgZ4VtdHN? MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
MG 63 (6-TG R) M1jMfJFJXFNiYYPzZZk> MnWxdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy| MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
NB1643 NHrBNJFyUFSVIHHzd4F6 NHS5Vo5yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
OHS-50 MXvxTHRUKGG|c3H5 MmrLdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?= MmfhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh41 MVLxTHRUKGG|c3H5 NX7aZoZ5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoOFEh[2WubIO= M3rqO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh30 NHK0VFFyUFSVIHHzd4F6 M2fGcZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEOwJINmdGy| MmnvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
LAN-5 MX;xTHRUKGG|c3H5 NXH0fGFueUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz NHvoc3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh18 M{nVXJFJXFNiYYPzZZk> Ml7qdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqMUigZ4VtdHN? MljJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Assay
Methods Test Index PMID
Western blot Cleaved-PARP-1 / Cleaved-caspase-3 / LC3-II / p62 / SIRT1 26655844
Immunofluorescence Cathepsin B 26655844
Growth inhibition assay Cell viability 25411356
In vivo In DIO mice SRT1720 mimics several of the effects observed after calorie restriction including improved insulin sensitivity, normalized glucose and insulin levels, and increased mitochondrial capacity. In addition, in diet-induced obese and genetically obese mice, SRT1720 improves insulin sensitivity, lower plasma glucose, and increase mitochondrial capacity. Thus, SRT1720 is a promising new therapeutic agent for treating diseases of ageing such as type 2 diabetes. Consistent with improved glucose tolerance, the glucose infusion rate required to maintain euglycaemia is approximately 35% higher in SRT1720-treated fa/fa rats, and the total glucose disposal rate is increased by approximately 20%. [1] SRT1720 also prevents multiple myeloma tumor growth. SRT1720 increases the cytotoxic activity of bortezomib or dexamethasone. [2]

Protocol (from reference)

Kinase Assay:[1]
  • SIRT1 fluorescence polarization assay:

    In the SIRT1 FP assay, SIRT1 activity is monitored using a 20 amino acid peptide (Ac-Glu-Glu-Lys(biotin)-Gly-Gln-Ser-Thr-Ser-Ser-His-Ser-Lys(Ac)-Nle-Ser-Thr-Glu-Gly–Lys(MR121 or Tamra)-Glu-Glu-NH2) derived from the sequence of p53. The peptide is N-terminally linked to biotin and C-terminally modified with a fluorescent tag. The reaction for monitoring enzyme activity is a coupled enzyme assay where the first reaction is the deacetylation reaction catalyzed by SIRT1 and the second reaction is cleavage by trypsin at the newly exposed lysine residue. The reaction is stopped and streptavidin is added in order to accentuate the mass differences between substrate and product. The sensitivity of the FP assay allows identification of SRT1720. The fluorescence polarization reaction conditions are as follows: 0.5 μM peptide substrate, 150 μM βNAD+, 0-10 nM SIRT1, 25 mM Tris-acetate pH 8, 137 mM Na-Ac, 2.7 mM K-Ac, 1 mM Mg-Ac, 0.05% Tween-20, 0.1% Pluronic F127, 10 mM CaCl 2, 5 mM DTT, 0.025% BSA, and 0.15 mM nicotinamide. The reaction is incubated at 37 °C and stopped by addition of nicotinamide, and trypsin is added to cleave the deacetylated substrate. This reaction is incubated at 37 °C in the presence of 1 μM streptavidin. Fluorescent polarization is determined at excitation (650 nm) and emission (680 nm) wavelengths.

Cell Research:[2]
  • Cell lines: Human vascular endothelial cells (HUVECs)
  • Concentrations: 5 μM
  • Incubation Time: 2 hours
  • Method: Transwell Insert Assays are utilized to measure migration. In vitro angiogenesis is assessed by Matrigel capillary-like tube structure formation assay. For endothelial tube formation assay, human vascular endothelial cells (HUVECs) are obtained from Clonetics and maintained in endothelial cell growth medium-2 containing 5% FBS. After three passages, HUVEC cell viability is measured with the trypan blue exclusion assay, and <5% of cell death is observed with SRT1720 treatment.
  • (Only for Reference)
Animal Research:[1]
  • Animal Models: Chase-SCID mice with MM.1S cells
  • Dosages: 200 mg/kg
  • Administration: Orally
  • (Only for Reference)

Solubility (25°C)

In vitro

DMSO 38 mg/mL
(75.09 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 506.02
Formula

C25H23N7OS.HCl

CAS No. 1001645-58-4
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1CN(CCN1)CC2=CSC3=NC(=CN23)C4=CC=CC=C4NC(=O)C5=NC6=CC=CC=C6N=C5.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
How can we prepare Srt1720 for in vivo mouse studies?

Answer:
SRT1720 HCl can be dissolved in 30% PEG 400+0.5% Tween 80+5% Propylene glycol at 30mg/ml as a suspension. It is fine for oral gavage. And we’ve also found that it can be dissolved in 2% DMSO+30% PEG 300+1%Tween 80+ddH2O at 3mg/ml clearly, which could be used for injection. When prepare the solution, please dissolve the compound in DMSO clearly first, then add PEG and Tween. After they mixed well, dilute with water.

Tags: buy SRT1720 HCl | SRT1720 HCl supplier | purchase SRT1720 HCl | SRT1720 HCl cost | SRT1720 HCl manufacturer | order SRT1720 HCl | SRT1720 HCl distributor